Urgent

Monoclonal antibody / biologic infusion reaction

Cytokine-release and hypersensitivity reactions to biologics · Allergy / Immunology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Reactions to therapeutic monoclonal antibodies include first-infusion cytokine-release reactions (fever, rigors, flushing, dyspnoea), IgE-mediated anaphylaxis (classically to the galactose-alpha-gal epitope on cetuximab) and delayed serum-sickness reactions. Distinguishing the mechanism directs rate adjustment, premedication or desensitisation.

Red flags

  • Hypotension, stridor or wheeze
  • Severe rigors with hypoxia
  • Reaction to cetuximab (alpha-gal anaphylaxis risk)
  • Delayed arthralgia, rash and fever (serum sickness)
  • Signs of tumour lysis during rituximab

Assessment

Differential diagnosis

  • Cytokine-release reaction (first infusion, non-IgE)
  • IgE-mediated anaphylaxis (e.g. cetuximab/alpha-gal, chimeric antibodies)
  • Serum sickness-like reaction (delayed)
  • Tumour lysis-related symptoms (rituximab in bulky disease)
  • Vasovagal reaction

Investigations

  • Document timing, infusion number and symptom pattern
  • Continuous monitoring during infusion
  • Mast cell tryptase after severe reactions
  • FBC and tumour lysis panel if rituximab in high tumour burden
  • Specific IgE (e.g. alpha-gal for cetuximab) where relevant

Management

  • Stop or slow the infusion at the first reaction and assess severity
  • Treat airway/cardiovascular compromise as anaphylaxis with IM adrenaline
  • Give antihistamine, corticosteroid, antipyretic and oxygen as indicated
  • For mild cytokine-release reactions, restart at a reduced rate once settled
  • Enhance premedication (antihistamine, paracetamol, corticosteroid) and slow the rate for subsequent infusions
  • Investigate for IgE sensitisation after anaphylaxis and arrange desensitisation if the drug is essential
  • Monitor for delayed serum-sickness reactions in the days after infusion
  • Document mechanism and grade; liaise with the treating specialty

Drugs & doses

Adrenaline IM — 500 mcg (0.5 mL 1:1000) for anaphylaxis
Chlorphenamine — 10 mg IV/IM for cutaneous/systemic symptoms
Hydrocortisone — 100-200 mg IV for moderate-severe reactions
Paracetamol — 1 g IV/oral for fever and rigors
Pethidine — 25 mg IV for severe rigors (if required)
Salbutamol — 5 mg nebulised for bronchospasm

Disposition

Observe after mild reactions and continue with premedication; refer significant hypersensitivity to allergy and admit anaphylaxis for monitoring.

Complications & pitfalls

  • Anaphylaxis
  • Serum sickness
  • Tumour lysis syndrome (rituximab)
  • Interruption of essential biologic therapy
  • Recurrent reactions despite premedication

Exam pearls

  • First-infusion reactions are usually cytokine-release and respond to slowing the rate with premedication
  • Cetuximab anaphylaxis is linked to pre-existing alpha-gal IgE and can occur on first exposure
  • Delayed arthralgia, rash and fever suggest serum sickness, not immediate allergy
  • Desensitisation allows continued use of an essential biologic after true hypersensitivity

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.